



## Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024

September 6, 2024

*Interim data to be reported for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3K $\alpha$ -mutated, HR+/HER2- metastatic breast cancer*

*Conference call to be held Monday, September 9, at 8am ET*

CAMBRIDGE, Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) -- [Relay Therapeutics, Inc.](https://www.relaytx.com) (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced plans to host a conference call and webcast to report data for RLY-2608 600mg BID + fulvestrant in the ongoing ReDiscover trial in patients with PI3K $\alpha$ -mutated, HR+/HER2- metastatic breast cancer and next steps on Monday, September 9, 2024, at 8:00 a.m. ET.

### Conference Call Information

Registration and dial-in for the conference call and webcast may be accessed through Relay Therapeutics' website under Events in the News & Events section through the following link: <https://ir.relaytx.com/news-events/events-presentations>. An archived replay of the webcast will be available following the event.

### About RLY-2608

RLY-2608 is the lead program in Relay Therapeutics' efforts to discover and develop mutant selective inhibitors of PI3K $\alpha$ , the most frequently mutated kinase in all cancers, with oncogenic mutations detected in about 14% of patients with solid tumors. RLY-2608 has the potential, if approved, to address more than 250,000 patients per year in the United States, one of the largest patient populations for a precision oncology medicine.

Traditionally, the development of PI3K $\alpha$  inhibitors has focused on the active, or orthosteric, site. The therapeutic index of orthosteric inhibitors is limited by the lack of clinically meaningful selectivity for mutant versus wild-type (WT) PI3K $\alpha$  and off-isoform activity. Toxicity related to inhibition of WT PI3K $\alpha$  and other PI3K isoforms results in sub-optimal inhibition of mutant PI3K $\alpha$  with reductions in dose intensity and frequent discontinuation. The Dynamo<sup>®</sup> platform enabled the discovery of RLY-2608, the first known allosteric, pan-mutant, and isoform-selective PI3K $\alpha$  inhibitor, designed to overcome these limitations. Relay Therapeutics solved the full-length cryo-EM structure of PI3K $\alpha$ , performed computational long time-scale molecular dynamic simulations to elucidate conformational differences between WT and mutant PI3K $\alpha$ , and leveraged these insights to support the design of RLY-2608. RLY-2608 is currently being evaluated in a first-in-human trial designed to treat patients with advanced solid tumors with a PIK3CA (PI3K $\alpha$ ) mutation. For more information on RLY-2608, please visit [here](#).

### About Relay Therapeutics

Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its Dynamo<sup>®</sup> platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit [www.relaytx.com](http://www.relaytx.com) or [follow us on Twitter](#).

### Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio, including the timing of clinical initiation of the RLY-2608 + atimociclib + fulvestrant triplet combination; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs; the potential market opportunity for RLY-2608; and the expected strategic benefits under Relay Therapeutics' clinical trial collaboration with Pfizer. The words "may," "might," "will," "could," "would," "should," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of global economic uncertainty, geopolitical instability, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; the delay of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in

the section entitled "Risk Factors" in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

**Contact:**

Megan Goulart

617-545-5526

[mgoulart@relaytx.com](mailto:mgoulart@relaytx.com)

**Media:**

Dan Budwick

1AB

973-271-6085

[dan@1abmedia.com](mailto:dan@1abmedia.com)